Mining Cancer Cell Line-Based Drugs to Benefit KRAS(G12D)Pancreatic Adenocarcinoma Patients

Aman Chandra Kaushik; Aamir Mehmood; Ajay Kumar; Ankit Babu; Dong Qing Wei; Zhongming Zhao

doi:10.1109/BIBM52615.2021.9669307

Mining Cancer Cell Line-Based Drugs to Benefit KRAS^(G12D)Pancreatic Adenocarcinoma Patients

Aman Chandra Kaushik
, Aamir Mehmood
, Ajay Kumar
, Ankit Babu
, Dong Qing Wei
, Zhongming Zhao

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

2 Scopus citations

Abstract

Pancreatic adenocarcinoma (PAAD) is one of the most challenging cancers with high morbidity and mortality. KRAS mutations could occur as an early event in PAAD. KRAS genes are highly mutated with recurrent mutations in various cancer types, including PAAD. We aim to depict the omics landscape of KRAS mutations and seek potential novel drugs for pancreatic cancer patients with KRAS mutations. This study used data from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) for KRAS mutation analysis in a multi-omics manner. We found that the genomics and transcriptomics patterns of KRAS mutations are significantly different compared to the corresponding non-KRAS-mutated PAAD samples. Pancreatic cancer's prognosis is directly associated with a specific KRAS mutation and its protein's structure instability. Our analysis confirmed that Irinotecan could be a potential drug for PAAD patients with KRASG12D mutation.

Original language	English
Title of host publication	Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021
Editors	Yufei Huang, Lukasz Kurgan, Feng Luo, Xiaohua Tony Hu, Yidong Chen, Edward Dougherty, Andrzej Kloczkowski, Yaohang Li
Publisher	Institute of Electrical and Electronics Engineers
Pages	2423-2428
Number of pages	6
ISBN (Electronic)	9781665401265
DOIs	https://doi.org/10.1109/BIBM52615.2021.9669307
State	Published - 1 Jan 2021
Externally published	Yes
Event	2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021 - Virtual, Online, United States Duration: 9 Dec 2021 → 12 Dec 2021

Publication series

Name	Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021

Conference

Conference	2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021
Country/Territory	United States
City	Virtual, Online
Period	9/12/21 → 12/12/21

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

KRAS
Mutation
PAAD
TCGA
transcriptomics pattern

ASJC Scopus subject areas

Artificial Intelligence
Computer Science Applications
Biomedical Engineering
Health Informatics
Information Systems and Management

Access to Document

10.1109/BIBM52615.2021.9669307

Cite this

Kaushik, A. C., Mehmood, A., Kumar, A., Babu, A., Wei, D. Q., & Zhao, Z. (2021). Mining Cancer Cell Line-Based Drugs to Benefit KRAS^(G12D)Pancreatic Adenocarcinoma Patients. In Y. Huang, L. Kurgan, F. Luo, X. T. Hu, Y. Chen, E. Dougherty, A. Kloczkowski, & Y. Li (Eds.), Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021 (pp. 2423-2428). (Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021). Institute of Electrical and Electronics Engineers. https://doi.org/10.1109/BIBM52615.2021.9669307

Kaushik, Aman Chandra ; Mehmood, Aamir ; Kumar, Ajay et al. / Mining Cancer Cell Line-Based Drugs to Benefit KRAS^(G12D)Pancreatic Adenocarcinoma Patients. Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021. editor / Yufei Huang ; Lukasz Kurgan ; Feng Luo ; Xiaohua Tony Hu ; Yidong Chen ; Edward Dougherty ; Andrzej Kloczkowski ; Yaohang Li. Institute of Electrical and Electronics Engineers, 2021. pp. 2423-2428 (Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021).

@inproceedings{c783001803fe493cad6fd5e2166e7e81,

title = "Mining Cancer Cell Line-Based Drugs to Benefit KRAS(G12D)Pancreatic Adenocarcinoma Patients",

abstract = "Pancreatic adenocarcinoma (PAAD) is one of the most challenging cancers with high morbidity and mortality. KRAS mutations could occur as an early event in PAAD. KRAS genes are highly mutated with recurrent mutations in various cancer types, including PAAD. We aim to depict the omics landscape of KRAS mutations and seek potential novel drugs for pancreatic cancer patients with KRAS mutations. This study used data from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) for KRAS mutation analysis in a multi-omics manner. We found that the genomics and transcriptomics patterns of KRAS mutations are significantly different compared to the corresponding non-KRAS-mutated PAAD samples. Pancreatic cancer's prognosis is directly associated with a specific KRAS mutation and its protein's structure instability. Our analysis confirmed that Irinotecan could be a potential drug for PAAD patients with KRASG12D mutation.",

keywords = "KRAS, Mutation, PAAD, TCGA, transcriptomics pattern",

author = "Kaushik, \{Aman Chandra\} and Aamir Mehmood and Ajay Kumar and Ankit Babu and Wei, \{Dong Qing\} and Zhongming Zhao",

note = "Publisher Copyright: {\textcopyright} 2021 IEEE.; 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021 ; Conference date: 09-12-2021 Through 12-12-2021",

year = "2021",

month = jan,

day = "1",

doi = "10.1109/BIBM52615.2021.9669307",

language = "English",

series = "Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021",

publisher = "Institute of Electrical and Electronics Engineers",

pages = "2423--2428",

editor = "Yufei Huang and Lukasz Kurgan and Feng Luo and Hu, \{Xiaohua Tony\} and Yidong Chen and Edward Dougherty and Andrzej Kloczkowski and Yaohang Li",

booktitle = "Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021",

address = "United States",

}

Kaushik, AC, Mehmood, A, Kumar, A, Babu, A, Wei, DQ & Zhao, Z 2021, Mining Cancer Cell Line-Based Drugs to Benefit KRAS^(G12D)Pancreatic Adenocarcinoma Patients. in Y Huang, L Kurgan, F Luo, XT Hu, Y Chen, E Dougherty, A Kloczkowski & Y Li (eds), Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021. Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021, Institute of Electrical and Electronics Engineers, pp. 2423-2428, 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021, Virtual, Online, United States, 9/12/21. https://doi.org/10.1109/BIBM52615.2021.9669307

Mining Cancer Cell Line-Based Drugs to Benefit KRAS^(G12D)Pancreatic Adenocarcinoma Patients. / Kaushik, Aman Chandra; Mehmood, Aamir; Kumar, Ajay et al.
Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021. ed. / Yufei Huang; Lukasz Kurgan; Feng Luo; Xiaohua Tony Hu; Yidong Chen; Edward Dougherty; Andrzej Kloczkowski; Yaohang Li. Institute of Electrical and Electronics Engineers, 2021. p. 2423-2428 (Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - Mining Cancer Cell Line-Based Drugs to Benefit KRAS(G12D)Pancreatic Adenocarcinoma Patients

AU - Kaushik, Aman Chandra

AU - Mehmood, Aamir

AU - Kumar, Ajay

AU - Babu, Ankit

AU - Wei, Dong Qing

AU - Zhao, Zhongming

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Pancreatic adenocarcinoma (PAAD) is one of the most challenging cancers with high morbidity and mortality. KRAS mutations could occur as an early event in PAAD. KRAS genes are highly mutated with recurrent mutations in various cancer types, including PAAD. We aim to depict the omics landscape of KRAS mutations and seek potential novel drugs for pancreatic cancer patients with KRAS mutations. This study used data from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) for KRAS mutation analysis in a multi-omics manner. We found that the genomics and transcriptomics patterns of KRAS mutations are significantly different compared to the corresponding non-KRAS-mutated PAAD samples. Pancreatic cancer's prognosis is directly associated with a specific KRAS mutation and its protein's structure instability. Our analysis confirmed that Irinotecan could be a potential drug for PAAD patients with KRASG12D mutation.

AB - Pancreatic adenocarcinoma (PAAD) is one of the most challenging cancers with high morbidity and mortality. KRAS mutations could occur as an early event in PAAD. KRAS genes are highly mutated with recurrent mutations in various cancer types, including PAAD. We aim to depict the omics landscape of KRAS mutations and seek potential novel drugs for pancreatic cancer patients with KRAS mutations. This study used data from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) for KRAS mutation analysis in a multi-omics manner. We found that the genomics and transcriptomics patterns of KRAS mutations are significantly different compared to the corresponding non-KRAS-mutated PAAD samples. Pancreatic cancer's prognosis is directly associated with a specific KRAS mutation and its protein's structure instability. Our analysis confirmed that Irinotecan could be a potential drug for PAAD patients with KRASG12D mutation.

KW - KRAS

KW - Mutation

KW - PAAD

KW - TCGA

KW - transcriptomics pattern

UR - https://www.scopus.com/pages/publications/85125169764

U2 - 10.1109/BIBM52615.2021.9669307

DO - 10.1109/BIBM52615.2021.9669307

M3 - Conference contribution

AN - SCOPUS:85125169764

T3 - Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021

SP - 2423

EP - 2428

BT - Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021

A2 - Huang, Yufei

A2 - Kurgan, Lukasz

A2 - Luo, Feng

A2 - Hu, Xiaohua Tony

A2 - Chen, Yidong

A2 - Dougherty, Edward

A2 - Kloczkowski, Andrzej

A2 - Li, Yaohang

PB - Institute of Electrical and Electronics Engineers

T2 - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021

Y2 - 9 December 2021 through 12 December 2021

ER -

Kaushik AC, Mehmood A, Kumar A, Babu A, Wei DQ, Zhao Z. Mining Cancer Cell Line-Based Drugs to Benefit KRAS^(G12D)Pancreatic Adenocarcinoma Patients. In Huang Y, Kurgan L, Luo F, Hu XT, Chen Y, Dougherty E, Kloczkowski A, Li Y, editors, Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021. Institute of Electrical and Electronics Engineers. 2021. p. 2423-2428. (Proceedings - 2021 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2021). doi: 10.1109/BIBM52615.2021.9669307